Leuprorelin 3-month-depot a new ganlenical formula of a well-established GnRH analogur for treatment of prostate cancer;Leuprorelinacetat 3-Monats-Depot - Ein neues galenisches Prinzip eines bewährten GnRH-Analogons zur Behandlung des Prostatakarznoms

Aktuelle Urologie

Volumn 27, Issue 5, 1996, Pages 281-286

  Eckart, O ^a   Tunn, U W ^a,c   Lubben G ^b   Kienle, E ^b  

^a GOETHE UNIVERSITY   (Germany)

^b Takeda Pharma GmbH   (Germany)

^c Klinikum Offenbach GmbH   (Germany)

Author keywords

3 month depot; Endocrine treatment; GnRH analogue; Leuprorelin acetate; Prostata cancer

Indexed keywords

EID: 7144219729     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1055608     Document Type: Article

References (14)

1. Bouchot, O., N. Lahlou. M. Roger. J. Blumberg, F. Dufour-Esquerré. S. Ispas: Phase II study of decapeptyl sustained release form (3 months) in patients with prostate cancer. Gynecol. Endocrinol. 10 Suppl. 1 (1996) Abstract No. 125
2. Debruyne, F. M. J., G. A. Dijkman: Advances and trends in hormonal therapy for advanced prostate cancer. Eur. Urol. 28 (1995) 177-188
3. Debruyne. F. M. J.: Zoladex 10,8 mg depot for prostate cancer. Gynecol. Endocrinol. 10 Suppl. 1 (1996) Absract No. 120
4. Eisenberger, M. A., P. J. O. Dwyer, M. A. Friedmann: Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach or prostatic carcinoma. J. Clin. Oncol. 43 (1986) 414-424
5. Fornara. P., D. Jocham: Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma. Urol. Int. 56 Suppl. 1 (1996) 18-22
6. Janknegt, R. A.: Buserelin 2-month implant in advanced prostate cancer -3-year inerim evaluation of a phase III study. Gynecol. Endocrinol. 10 Suppl. 1 (1996) Abstract No. 121
7. Kienle, E., G. Lübben. The German Leuprorelin Study Group: Efficacy and safety of leuprorelin acetate depot for prostate cancer. Urol. Int. 56 Suppl. 1 (1996) 23-30
8. Mazzei, T., E. Mini. M. Rizzio. P. Periti: Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients. J. Internat. Med. Res. 18 Suppl. 1 (1990) 42-56
9. Oesterling, J. E., S. K. Martin, E. J. Bergstralh, F. C. Lowe: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269 (1993) 57-60
10. Ogawa, Y., H. Okada. T. Heya, T. Shimamoto: Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals. J. Pharm. Pharmacol. 41 (1989) 439-444
11. Okada, H., M. Yamamoto, H. Toshiro, Y. Inoue: Drug delivery using biodegradable microspheres. Journal of Controlled Rlease 28 (1994) 121-129
12. Okada, H., Y. Doken, Y. Ogawa, H. Toguchi: Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers. Pharmaceutical Research 118 (1994) 1143-1147
13. Okada, H., Y. Doken, Y. Ogawa, H. Toguchi: Sustained suppression of the pituitary-gonadal axis by leuprorelin three-month depot microspheres in rats and dogs. Pharmaceutical Research 118 (1994) 1199-1203
14. Yamazaki, I., H. Okadal: A radioimmunoassay for a highly active luteinizing hormone-releasing hormone analogue and relation between the serum level of the analogue and that of gonadotropin. Endocrinol. Japn. 27 (1980) 593-605